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Previous studies revealed a paradox whereby mitogen-acti-
vated protein kinase kinase kinase kinase 4 (Map4k4) acted as a
negative regulator of insulin sensitivity in chronically obese
mice, yet systemic deletion of Map4k4 did not improve glucose
tolerance. Here, we report markedly reduced glucose-respon-
sive plasma insulin andC-peptide levels in whole bodyMap4k4-
depleted mice (M4K4 iKO) as well as an impaired first phase of
insulin secretion from islets derived from M4K4 iKO mice ex
vivo. After long-term high fat diet (HFD), M4K4 iKOmice pan-
creata also displayed reduced  cell mass, fewer proliferating 
cells and reduced islet-specific gene mRNA expression com-
paredwith controls, although insulin contentwasnormal. Inter-
estingly, the reduced plasma insulin inM4K4 iKOmice exposed
to chronic (16weeks)HFDwasnot observed in response to acute
HFD challenge or short term treatment with the insulin recep-
tor antagonist S961. Furthermore, the improved insulin sensi-
tivity in obeseM4K4 iKOmicewas abrogatedbyhigh exogenous
insulin over the course of a euglycemic clamp study, indicating
that hypoinsulinemia promotes insulin sensitivity in chronically
obese M4K4 iKO mice. These results demonstrate that protein
kinase Map4k4 drives obesity-induced hyperinsulinemia and
insulin resistance in part by promoting insulin secretion from
cells in mice.
Highly controlled inter-organ networks operate to achieve
proper blood glucose regulation, which is essential formamma-
lian survival (1). Pancreatic  cell function is a major contribu-
tor to control of glucose homeostasis by secreting the hormone
insulin, which binds the insulin receptor to promote glucose
uptake in peripheral tissues including muscle and adipose tis-
sue while suppressing hepatic glucose production. In obesity,
insulin often fails to adequately promote peripheral glucose
uptake and suppress hepatic glucose production, resulting in
hyperglycemia, which is associated with a state described as
insulin resistance (2, 3). This insulin-resistant state promotes
an increase in pancreatic  cell mass (4) and enhanced insulin
secretion (5, 6) to normalize glucose levels, which results in
hyperinsulinemia. Obese and insulin-resistant patients eventu-
ally display  cell dysfunction, resulting in an inability to con-
trol glycemia, and type 2 diabetes (T2D)4 ensues (5).
Interestingly, recent evidence suggests that although hyper-
insulinemia is beneficial to restore euglycemia acutely, the
actions of chronically high insulin levels can promote adipose
tissue dysfunction and insulin resistance (7, 8). Treatments to
improve peripheral insulin sensitivity, suppress hepatic glucose
output, and potentiate pancreatic  cell insulin secretion are
mainstays of T2D treatment. However, these treatments are
often insufficient to fully control glucose homeostasis (9). T2D
is an enormous burden on the health care system because of its
association with a number of comorbidities including cardio-
vascular disease; thus further therapeutics are required.
Our laboratory identified the protein kinase mitogen-acti-
vated protein kinase kinase kinase kinase 4 (Map4k4) as a neg-
ative regulator of insulin-mediated glucose transport (10). We
observed that inducible whole-body Map4k4 gene deletion in
adult mice generated by crossing Map4k4-floxed mice to ubc-
ERT2 cre mice improved insulin sensitivity but not glucose tol-
erance (11). By selectively deleting Map4k4 in different cell
types in vivo, the increased insulin sensitivity in the whole body
knock-out was attributed at least in part to Map4k4 within a
myogenic factor 5 (myf 5)-positive lineage (11).
Here, we demonstrate that inducible, systemic loss of
Map4k4 ameliorates long-term HFD-induced hyperinsuline-
mia. Mice lacking Map4k4 (M4K4 iKO) fed HFD for 16 weeks
displayed reduced insulin secretion in vivo and a blunted  cell
hypertrophic response. However, a short-term high fat diet
(HFD; 4 weeks) or acute treatment of chow-fed control and
M4K4 iKO mice with the peptide insulin receptor antagonist
S961 induced similar hyperinsulinemia, suggesting that
Map4k4 is required for chronic adaptation but not an acute
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response to systemic insulin resistance. The reduction in insu-
lin levels in M4K4 iKO mice after chronic HFD was at least
partially mediated by reduced insulin secretion from the  cell,
as islets isolated from HFD-fed mice lacking Map4k4 demon-
strated a reduced first phase of glucose-induced insulin secre-
tion concomitant with reduced islet-specific gene expression.
Thus,Map4k4mediates hyperinsulinemia in chronic obesity by
promoting islet hypertrophy and insulin secretion from pan-
creatic  cells.
Results
Mature Mice Inducibly Lacking Map4k4 Are Not More Insu-
lin Sensitive in a Euglycemic Clamp—Previous reports fromour
laboratory described whole body inducible Map4k4 knock-out
mice, which were generated by crossing Map4k4 Flox/Flox
mice (Flox/Flox) to a tamoxifen-inducible ubiquitin cre system
(Ubc-ERT2Cre) (11) (M4K4 iKO). Though they displayed sim-
ilar bodyweight and fatmass, long-termhigh fat diet (HFD)-fed
M4K4 iKO animals displayed enhanced peripheral insulin sen-
sitivity in an ITT compared with Flox/Flox animals (11). To
further characterize this insulin sensitivity phenotype, we sub-
jected Flox/Flox and M4K4 iKO mice to a hyperinsulinemic-
euglycemic clamp after 16 weeks of HFD (Fig. 1A), and no dif-
ferences were observed between genotypes in clamped glucose
levels (Fig. 1B), glucose infusion rate (Fig. 1C), hepatic glucose
production (Fig. 1D), or glucose turnover (Fig. 1E). We had
previously reported that insulin levels were dramatically
reduced in HFD-fed M4K4 iKO mice compared with controls
(11).We thus hypothesized that thematched, increased insulin
levels during the hyperinsulinemic-euglycemic clampmayhave
masked the improved insulin sensitivity in M4K4 iKO mice,
andM4K4 iKOmicemay display enhanced insulin sensitivity in
an ITT in part due to lower insulin levels during this test. We
therefore sought to assess whether Map4k4 had a role within
the islet to control insulin secretion.
Map4k4 Is Present inCells andContributes to ChronicObe-
sity-induced Hyperinsulinemia—Fasting plasma insulin levels
were unchanged in chow-fed M4K4 iKO mice compared with
Flox/Flox controls (Fig. 2A). However, whereas insulin levels
significantly increased in response to glucose injection in Flox/
Flox animals (0.77 0.10 versus 1.14 0.10 ng/ml), there was
no significant increase in M4K4 iKO mice (0.76  0.12 versus
0.95 0.13 ng/ml; Fig. 2A), suggesting that insulin secretion in
vivo may be reduced or delayed in M4K4 iKO mice. Similar
results were observed after Flox/Flox and M4K4 iKO animals
were fed HFD for 4 weeks, as both Flox/Flox and M4K4 iKO
mice demonstrated similar basal insulin levels (1.66  0.21
ng/ml versus 1.62  0.20 ng/ml; Fig. 2B), which were signifi-
cantly increased from that observed in chow-fed animals (Fig.
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FIGURE 1. Similar glycemic control in hyperinsulinemic Flox/Flox andM4K4 iKOmice.Map4k4 Flox/Flox or Flox/Flox ubc-ERT2 cre animals were injected
with tamoxifen for 5 days at 6–8 weeks of age. After 2 weeks, the mice were placed on chow or a HFD for 16 additional weeks. A, injection scheme. B–D,
hyperinsulinemic euglycemic clampswere performed after aHFD for 16weeks. B, clampglucose.C, glucose infusion rate.D, hepatic glucose output. E, glucose
turnover. (Data are mean S.E., n 4, 6.)
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2A). However, while 16 weeks of HFD promoted further hyper-
insulinemia in Flox/Flox animals compared with chow-fed or 4
weeks HFD-fed counterparts (0.77 0.10 ng/ml chow, 1.66
0.21 ng/ml 4 weeks HFD, 2.96 0.47 ng/ml 16 weeks HFD; Fig.
2, A–C), M4K4 iKO animals did not display HFD-induced
hyperinsulinemia (0.76 0.12 ng/ml chow, 1.15 0.12 ng/ml
16 weeks HFD; Fig. 2, A–C). Furthermore, insulin levels signif-
icantly increased in Flox/Flox animals in response to an i.p.
glucose injection, (2.96  0.47 versus 4.72  0.52 ng/ml; Fig.
2C), which was not evident in M4K4 iKO animals (1.15 0.12
versus 1.86 0.23 ng/ml; Fig. 2C). These data suggest that sys-
temic loss of Map4k4 ameliorates chronic obesity-induced
hyperinsulinemia in vivo.
To assess whether insulin levels were decreased in HFD-fed
M4K4 iKOmice due to changes in insulin secretion, C-peptide
levels were measured. C-peptide is secreted in an equimolar
ratio to insulin and has a constant clearance rate; therefore, it is
a useful parameter to assess insulin secretion by cells aswell as
insulin clearance (14). Similar to insulin levels, 16 weeks HFD-
fed M4K4 iKO mice displayed reduced C-peptide levels both
basally and in response to a bolus glucose injection (891.9 
87.4 pg/ml versus 1602.4  226.2 pg/ml, and 478.5  67.95
pg/ml versus 792.88  148.0 pg/ml, respectively; Fig. 2D).
These data suggest that systemic Map4k4 is required for HFD-
induced hyperinsulinemia.
Pancreatic islets are comprised of and cells, andwhile the
 cell controls glucose-induced insulin secretion, the cell con-
trols fasting-induced glucagon secretion (15). However, no
alterations in plasma glucagon levels were noted in chow-fed or
HFD-fed Flox/Flox andM4K4 iKOmice after an overnight fast
(Fig. 2E). These data suggest that Map4k4 is required for pan-
creatic  but not  cell function in vivo in obese mice.
To determinewhetherMap4k4was indeed expressed in pan-
creatic islets in vivo and could potentiate hyperinsulinemia,
islets were isolated from Flox/Flox animals fed chow or HFD,
mRNAwas extracted, andMap4k4mRNA levels were assessed
and normalized to 36b4. A 3-fold increase in Map4k4 mRNA
expression was noted in Flox/Flox animals fed HFD for 16
weeks compared with chow diet (Fig. 2F), suggesting that
Map4k4 may contribute to HFD-induced hyperinsulinemia in
an islet-specific manner.
M4K4 iKOMice Can Effectively Secrete Insulin in Response to
Acute Stress—Insulin resistance promotes a compensatory
increase in insulin levels via pancreatic  cell proliferation and
enhanced insulin secretion to maintain homeostasis (16).
Thus, to assess whether Map4k4 insulin secretion in M4K4
iKO animals could still respond to acute stress induced by
insulin resistance, chow-fed Flox/Flox orM4K4 iKO animals
were made systemically insulin resistant using the peptide
insulin receptor antagonist S961, which indirectly as a con-
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FIGURE 2. Reduced insulin levels in HFD-fedM4K4 iKO compared with Flox/Flox mice. Control Flox/Flox and M4K4 iKOmice were fed chow or HFD for 4
or 16 weeks post injections. A–E, Flox/Flox and M4K4 iKOmice were fasted overnight, and insulin or C-peptide levels were assessed basally and/or 30 after 1
g/kg glucose injection. A, chow-fed insulin levels. B, 4 weeks HFD-fed insulin levels. C, 16 weeks HFD-fed insulin levels. D, 16 weeks HFD-fed C-peptide levels.
E, plasma glucagon levels in overnight fasted chow- and 16 weeks HFD-fed animals. F, islets were isolated from Flox/Flox control mice, and qRT-PCR was
performed forMap4k4 and normalized to 36b4. (n 6–10, *, p 0.05; **, p 0.005; #, p 0.0001). Data are mean S.E.
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sequence of insulin resistance potently induces  cell prolif-
eration and insulin secretion (17, 18). Mice were implanted
with a minipump subcutaneously 3–4 weeks after tamoxifen
administration and treated with 10 nmol of S961 or vehicle
for 1 week, and GTTs and ITTs were performed prior to
sacrifice (Fig. 3A). Islets isolated from animals after S961
treatment demonstrated over 95% deletion of Map4k4
mRNA using this protocol (Fig. 3B).
We have previously reported that there were no differences
in basal glucose tolerance or insulin sensitivity in chow-fed
Flox/Flox and M4K4 iKO mice (11). Indeed, vehicle-treated
M4K4 iKO animals displayed no differences in glucose toler-
ance or insulin sensitivity compared with Flox/Flox controls
(Fig. 3, C and D). As has been previously reported (17), S961
treatment induced glucose intolerance and insulin resistance in
both Flox/Flox and M4K4 iKO animals to a similar extent
within a 7-day period (Fig. 3, C and D). After 1 week of treat-
ment with S961, plasma insulin and C-peptide levels were
assessed after a 4-h fast. In vehicle-treatedmice, similar levels of
plasma insulin (Fig. 3E) and C-peptide (Fig. 3F) levels were
observed. However, while a long-term HFD caused hyperinsu-
linemia in Flox/Flox animals but not M4K4 iKO mice (Fig. 2),
acute S961 treatment induced both plasma insulin as well as
C-peptide levels to a similar extent in both genotypes (Fig. 3, E
and F). Taken together, these data suggest that Map4k4 is not
required to mediate hyperinsulinemia in response to acute
stress but is required formaintaining insulin levels in long term
HFD stress (Fig. 2).
FIGURE 3. Acute insulin resistance increases plasma insulin levels in Flox/Flox and M4K4 iKO mice. 3–4 weeks after tamoxifen treatment, chow-fed
Flox/Flox andM4K4 iKOmicewere treatedwith 10 nmol of S961 or vehicle for 1week byminipump.A, experimental timeline. B, islets were isolated onD8, and
quantitative RT-PCR was performed for Map4k4 and normalized to 36b4 (#, p 0.0005; n 5). C, mice were subjected to an i.p. GTT on day 6. D, mice were
subjected to an i.p. ITT on day 7. E, plasma insulin levels were measured after a 4 h fast on day 8. F, plasma C-peptide levels were measured after a 4-h fast on
day 8 (*, p 0.05; **, p 0.005; n 5–6 vehicle, 11–12 S961). Data are mean S.E.
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Normal Islet Morphology and Gene Expression in M4K4 iKO
Mice—To better understand how Map4k4 ameliorated HFD-
induced hyperinsulinemia, gene expression was next assessed
in primary islets isolated from 16-week HFD-fed Flox/Flox or
M4K4 iKOmice.Whereas a highly significant 70% reduction in
Map4k4 gene expression was observed in islets and a similar
reduction in Map4k4 protein expression was observed in
immunoblots ofwhole pancreata thatwere isolated fromM4K4
iKO mice (Fig. 4, A and B), no significant changes were
observed in islet insulin (Ins1) or glucagon (Gcgn)mRNA levels,
although a trend to a reduction in Ins2 mRNA levels were
observed (Fig. 4A). Similar islet morphology was also observed
in 16-week HFD-fed Flox/Flox and M4K4 iKO pancreata as
assessed by immunofluorescence for insulin ( cells) and glu-
cagon ( cells) (Fig. 4C). These data suggest that loss ofMap4k4
is not critical for general islet maintenance in obesity.
Reduced Islet Mass in Obese M4K4 iKO Mice—Loss of
Map4k4 did not affect islet morphology in obese mice, but this
does not exclude the possibility that Map4k4 may affect overall
 cell mass or function. Thus,  cell mass was quantified by
immunohistochemical staining for insulin as a percentage of
pancreas mass in chow and 16 weeks HFD-fed Flox/Flox and
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M4K4 iKO animals. In chow animals,  cell mass was slightly
increased (1.15  0.22 versus 2.12  0.17 mg; Fig. 4E). As
expected, islet mass significantly increased after a 16-week
HFD in Flox/Flox animals (1.15  0.22 versus 3.39  0.58 mg;
Fig. 4E), whereas no such increase occurred in M4K4 iKO ani-
mals (2.12 0.17 versus 1.82 0.13 mg; Fig. 4E), which was a
significant 76% reduction compared with Flox/Flox animals
after 16-weeks of HFD (Fig. 4, D and E).
Increased islet mass may be mediated by  cell proliferation
(16, 19, 20); thus,  cell proliferation rates were estimated by
assessing the percentage of insulin-positive cells in HFD-fed
animals that also expressedKi67, amarker of proliferating cells,
using immunofluorescence (Fig. 4F). Indeed, 16-weekHFD-fed
M4K4-iKO mice displayed a significant 58% reduction in the
percentage of Ki67/insulin-positive cells compared with con-
trolmice (0.57% 0.09 versus 0.24% 0.03; Fig. 4G), consistent
with the reduction that was observed in islet mass (Fig. 4,D and
E). Furthermore, the reduction in islet mass was not likely due
to enhanced cell death as the expression of apopto-
sis-associated genes Txsnip, Casp 3, or spliced XBP were not
increased in islets that had been isolated from 16-week HFD-
fed control or iKO mice (Fig. 4H). These results suggest that
Map4k4promotesHFD-induced cell expansion by enhancing
proliferation.
Reduced Insulin Secretion in Islets Derived from HFD-fed
M4K4 iKO Mice—In addition to islet mass, we assessed
whether Map4k4 may also regulate islet function and insulin
secretion. Thus, islets were isolated from HFD-fed Flox/Flox
and M4K4 iKO animals, and qRT-PCR was performed for
genes that are important for islet function. Consistent with a
role forMap4k4 in cell function,mRNA levels of islet-specific
genes including Pancreatic and duodenal homeobox 1 (Pdx-1),
v-maf musculoaponeurotic fibrosarcoma oncogene family,
protein A (Mafa), and Mafb were significantly decreased, and
levels ofNkx6.1 were also reduced in islets derived fromM4K4
iKOmice (Fig. 5A). The reduction inMaf A protein expression
in M4K4 iKO islets was additionally confirmed by immuno-
staining pancreas sections from HFD-fed Flox/Flox or M4K4
iKOanimals (Fig. 5C). Glucose sensing is also critical for insulin
secretion, and several genes including glut-2 (Slc2a2) and glu-
cokinase (Gck) are responsible for this response. Though no
significant changes were observed in Slc2a2mRNA expression,
Gck expression was significantly reduced in iKO mouse islets
compared with those derived from Flox/Flox animals (Fig. 5B),
suggesting that islets lackingMap4k4 expressionmay not prop-
erly sense the slow rise in glucose that occurs during HFD-
induced obesity.
Glucose-induced insulin secretion was functionally assessed
ex vivo in islets derived from chow or HFD-fed Flox/Flox and
M4K4 iKOmice using a perifusionmodel inwhichmediumwas
collected every 1–3 min to assess insulin secretion basally (3
mM glucose) as well as after the addition of 20mM glucose or 20
mM KCl. As expected (21), high glucose concentrations
enhanced insulin secretion in Flox/Flox islets in a biphasic
manner, with a rapid peak (1st phase) of insulin secretion occur-
ring very shortly after introduction of 20 mM glucose at
minute 30, followed by a prolonged (minute 35 to 50) 2nd
phase of insulin secretion (Fig. 5, D–G). Interestingly, though
islets derived from chow-fedM4K4 iKOmice displayed similar
insulin secretion (Fig. 5, D and E), islets isolated from HFD-fed
M4K4 iKO mice displayed a significant attenuation in this 1st
phase of insulin secretion (Fig. 5, F and G), which is one of the
earliest detectable signs of  cell dysfunction in those destined
to develop type 2 diabetes, which occurs prior to changes in
plasma glucose levels (22–24). This reduction in the first phase
of insulin secretion in HFD-fed M4K4 iKO mice is also a pri-
mary characteristic of  cell dysfunction. These data suggest
that loss ofMap4k4 reduces not only cellmass (Fig. 4) but also
impairs cell function and glucose-induced insulin secretion in
obese mice under long-term stress, possibly due to abnormal
glucose sensing (Fig. 5).
Discussion
Secretion of insulin by pancreatic  cells is critical to pro-
mote peripheral glucose uptake andmaintain euglycemia when
glucose levels rise (3). Insulin secretion can be regulated on a
tissue level by increasing  cell mass and number through pro-
liferation or on a cell autonomous level by altering  cell depo-
larization, or both (5). However, increased physiological
demand for insulin, such as in insulin resistance, can lead to 
cell dysfunction and type 2 diabetes (5). Therefore, it is neces-
sary to understand the physiological signals that lead to
demand-induced  cell proliferation and insulin secretion.
We had previously demonstrated that inducible, systemic
loss of Map4k4 in adult mice improved insulin sensitivity (11).
Here, we expand upon these observations with the unexpected
finding that this improved sensitivity is at least in part due to
reduced insulin levels in M4K4 iKO mice. Thus, under hyper-
insulinemic euglycemic clamp conditions, no difference in glu-
cose infusion rates betweenM4K4 iKOmice and controls in the
context of hyperinsulinemia were observed (Fig. 1). These data
indicate that hyperinsulinemia over the course of these clamp
studies reverses the increased insulin sensitivity induced by
chronically low insulin levels in M4K4 iKO mice.
We sought to explain the reduced insulin levels observed
after HFD in M4K4 iKO mice. Short-term (4 weeks) HFD as
well as acute hyperinsulinemia mediated by systemic insulin
resistance in response to S961 treatment did not reveal a
marked difference in insulin levels between genotypes (Figs. 2
and 3), suggesting that long-term adaptive mechanisms rather
than a primary defect in secretion may be more important in
establishing the reduced insulin phenotype observed in HFD-
fed M4K4 iKO mice. In support of this hypothesis, reduced 
cell mass and proliferation were observed in M4K4 iKO mice
after long-termHFD (Fig. 4). Furthermore, expression of genes
that determine  cell specification and insulin secretion were
reduced in islets that had been isolated fromobesemice lacking
Map4k4 (Fig. 5), suggesting that islet-specificMap4k4 is impor-
tant for mediating long-term adaptation to metabolic stress.
Mice lacking systemic Map4k4 displayed reduced  cell
hypertrophy in obesity compared with Flox/Flox counterparts,
at least in part due to reducedHFD-induced  cell proliferation
(Fig. 4). Recent studies suggest that  cell proliferation is
required for  cell expansion in obesity and in times of
increased insulin demand because most  cell expansion is
mediated by self-replication (16, 19, 20). In obesity, several
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physiological signals including neuronal inputs (25), microvas-
cular dysfunction (26), and paracrine hormonal regulation (27)
are also important for  cell function on a systemic level.
Because themice described herein utilize ubiquitin cre to delete
Map4k4 systemically, a specific cell type that is mediating these
effects on insulin levels is difficult to delineate. Important
future studies will include defining a cell-autonomous role for
Map4k4 in the pancreatic  cell using mouse insulin promoter
(Mip-1) cre animals (28).
It is unclear whyMap4K4 iKOmice displayed similar insu-
lin levels after acute challenge to the pancreas such as in 4
weeks of HFD or after S961 treatment. It is possible that
factors related to the high lipid content of HFD may mediate
these effects on the  cell, as  cells are susceptible to lipo-
toxicity (29). Another possibility is that the acute insulin
resistance stimulus mediated by S961 treatment was too
short to observe a more adaptive effect in M4k4 iKO mice.
Perhaps a sub-maximal dose of S961 treatment over a longer
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FIGURE 5. Reduced isletspecific gene expression and insulin secretion in M4K4 iKO islets. Flox/Flox and M4K4 iKO mice were fed HFD for 16 weeks
following tamoxifen treatment. A and B, islets were isolated, and quantitative RT-PCR was performed for the indicated genes and normalized to 36b4 (*, p
0.05; n  10). C, pancreata were isolated and immunostained for Maf-A. Data are representative of 4 per genotype. D–G, islets were isolated, and glucose-
induced insulin secretion was performed. Insulin levels are shown from isolated islets in response to 20 mM glucose and KCl as a percentage of total insulin
released upon KCl treatment. D and E, chow fed animals, E, higher magnification of square box from D. F and G, HFD-fed animals. G, higher magnification of
square box from F (*, p 0.05; n 4). Data are mean S.E.
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time period would have a different effect on insulin secretion
in this context.
Previous studies have implicated a cell autonomous role for
Map4k4 in glucose-induced insulin secretion in vitro using a rat
 cell line. Bouzraki et al. (30) suggested that deletion of
Map4k4 ameliorated the TNF--induced decrease in glucose-
induced insulin secretion in vitro, andZhao et al. (31) suggested
that Map4k4 is a target of miRNA-30d, which induces insulin
gene expression in  cells. Both of these studies report that
Map4k4 expression is inhibitory to insulin gene expression and
insulin secretion, yet our in vivo studies reveal that loss of
Map4k4 in islets of HFD-fed mice actually reduced insulin
secretion from  cells ex vivo. Furthermore, while Bouzakri et
al. demonstrated that loss of Map4k4 in cultured  cells
induced Mafa and Pdx-1 gene expression (30), Map4k4 iKO
mice demonstrated reduced Mafa and Pdx-1 gene expression
in primary islets (Fig. 5A). Interestingly, we also observed
enhanced Pdx-1 and Mafa gene expression upon Map4k4
silencing in the Min6  cell line, similar to Bouzakri et al. (not
shown). These results suggest that there are fundamental dif-
ferences in the roles of Map4k4 in pancreatic islets and  cell
culture lines, which will be explored in future studies.
The mechanism by which Map4k4 regulates plasma insulin
levels remains unclear. Other studies have implicated the
related ste-20-like kinaseMST-1 as a positive regulator of cell
apoptosis in diabetes, and loss of MST-1 promoted normogly-
cemia in diabetic animal models (32). In our studies,  cell apo-
ptosis was assessed both by gene expression analysis (Fig. 4) and
TUNEL staining (data not shown), and little to no apoptosis
was observed in either control orMap4k4 iKOmice using these
methods.  cell failure in diabetes is also attributed to de-dif-
ferentiation of  cells into other endocrine cells (33). However,
glucagon and insulin staining in M4K4 iKO islets after long-
term HFD revealed normal and uniform staining (Fig. 4), sug-
gesting that Map4k4 loss is not promoting islet de-differentia-
tion. Thus, future studies will be required to determine the
molecular targets ofMap4k4 thatmediate its function in cells.
In summary, we have demonstrated that Map4k4 is required
for chronic HFD-induced hyperinsulinemia in mice. Map4k4
promoted islet expansion in obesity, and islets derived from
Map4k4 iKO mice demonstrated reduced insulin secretion ex
vivo (Fig. 5). These data support a complex role for Map4k4 in
physiology to regulate not only glucose uptake and insulin sen-
sitivity, but also the secretion of insulin itself and further sug-
gest that Map4k4 is a critical protector against  cell failure in
chronic overnutrition.
Experimental Procedures
Animal Studies—All of the studies performedwere approved
by the Institutional Animal Care and Use Committee (IACUC)
of the University of Massachusetts Medical School. Map4k4
Flox/Flox-UBC-cre ERT2 animals and tamoxifen dosing have
been previously described (11). Animals were maintained in a
12 h light/dark cycle. Mice were fed chow or HFD (Research
diets 12942i) for 4 or 16 weeks starting 2 weeks post tamoxifen
injections. Mice were euthanized by CO2 inhalation followed
by bilateral pneumothorax.
Glucose and Insulin Tolerance Tests—HFD-fed mice were
fasted for 16 h for a glucose tolerance test (GTT) or for 4 h for an
insulin tolerance test (ITT). S961-treated mice were fasted for
4 h before both tests. Fasted mice were i.p.-injected with glu-
cose (1 g/kg) or insulin (1 IU/kg). In vivo insulin secretion stud-
ies were assessed from blood drawn from the tail vein 30 after
glucose injection. Blood glucose levels were determined using a
Breeze-2 glucose meter (Bayer).
S961 Experiments—3–4 weeks post tamoxifen treatment,
chow-fed mice were anesthetized with isoflurane, and Alzet
2001 minipumps (Alzet) containing 10 nmol of S961 peptide
(Phoenix Pharmaceuticals) or equivalent vehicle (5% DMSO in
PBS) were implanted subcutaneously for 1 week. A GTT and
ITT were performed after a 4-h fast on days 6 and 7, respec-
tively, and mice were sacrificed on day 8 after a 4-hour fast.
Hyperinsulinemic Euglycemic Clamp Studies—The clamp
study was performed by the National MouseMetabolic Pheno-
typingCenter atUMass. 16-weekHFD-fedmicewere subjected
to an overnight fast, and a 2-h hyperinsulinemic-euglycemic
clamp was conducted in awake mice with a primed and contin-
uous infusion of human insulin (150 mU/kg body weight prim-
ing followed by 4mUkg-1min-1; Humulin, Eli Lilly). During the
clamp, 20% glucose was infused at variable rates to maintain
euglycemia (12).
Quantitative RT-PCR—RNA was isolated from primary
islets, and quantitative RT-PCR was performed as previously
described (11). Primer sequences are as follows: 36b4 (5-TCC-
AGGCTTTGGGCATCA-3, 3-CTTTATCAGCTGCACAT-
CACTCAGA-5); Map4k4 (5-CATCTCCAGGGAAATC-
CTCAGG-3, 3-TTCTGTAGTCGTAAGTGGCGTCTG-5);
Ins1 (5-CCATCAGCAAGCAGGTCATTG-3, 3-TGTGTA-
GAAGAAGCCACGCTCC-5); Ins2 (5-CAGAAACCATCA-
GCAAGCAGG-3, 3-TTGACAAAAGCCTGGGTGGG-5);
Gcgn (5-GAGGAACCGGAACAACATTGC-3, 3-GCAAT-
GAATTCCTTTGCTGCC-5); Slc2a2 (5-TGCTGCTGGA-
TAAATTCGCC-3, 3-TCAGCAACCATGAACCAAGG-3);
Mafa (5-AGGAGGAGGTCATCCGACTG-3, 3-CTTCTC-
GCTCTCCAGAATGTG-5); Mafb (5-AGGACCTGTACTG-
GATGGC-3, 3-CACTACGGAAGCCGTCGAAG-5); Nkx6.1
(5-CTTCTGGCCCGGAGTGATG-3, 3-GGGTCTGGTG-
TGTTTTCTCTTC-5); Pdx-1 (5-GAGGTGCTTACACA-
GCGGAA-3, 3-GGGGCCGGGAGATGTATTT-5), gck,
(5-TGAGCCGGATGCAGAAGGA-3, 3 AGGCCAGTG-
TAAAGATGTTGC-5), txsnip (5-TCCTCAAGATGGGTG-
GCAAT-3, 3-GGCGTTGTCTTTCCAAGGTT-5), xbp_s
(5-CTGAGTCCGAATCAGGTGCAG-3, 3-CCAGAACA-
TCTTCCCATGGAC-5), Casp3 (5-CAGCCAACCTCAGA-
GAGACA-3, 3-TCACACACACAAAGCTGCTC-5).
Plasma Biochemical Analysis—Mice were fasted overnight
or for 4 h, and plasma was collected via tail vein or cardiac
puncture. Plasma insulin, C-peptide, and glucagon levels were
assessed using insulin (Millipore), C-peptide (ALPCO), or glu-
cagon (R&D systems) ELISAs, respectively, according to the
manufacturer’s instructions. Glucagon levels were measured
immediately upon blood collection. Insulin levels from perifu-
sion analysis and isolated islets were alsomeasured by ELISA as
above.
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Histology—Mouse pancreata were isolated and fixed in 10%
formalin for 4 h followed by paraffin embedding and sectioning.
Slides were stainedwith hematoxylin, insulin (abcam ab7842 or
ab6995), glucagon (abcam ab10988), Ki67 (abcam ab16667 or
ab6526), or Maf-A (ab17976). The ratio of -cell area to total
pancreas area was calculated from one or the average of 2 his-
tological images (one superficial, one deep) using BioPix soft-
ware by selecting the insulin-positive (brown) area as a percent-
age of total pancreas area (blue) and multiplying by the wet
weight of the pancreas to obtain  cell mass in mg.
Western Blotting Analysis—Whole pancreata were harvested
and snap frozen in liquid nitrogen followed by lysis and sonica-
tion (150 mM Tris, 2% SDS, 1% Triton, 5 mM EDTA, 2HALT
protease, and phosphatase inhibitors (Thermo Pierce)). SDS-
PAGE gels were run and transferred to nitrocellulose mem-
branes. Membranes were immunoblotted with anti-Map4k4
(Bethyl) or -tubulin (Sigma) antibodies.
Islet Isolation and Insulin Secretion—Islets were isolated
from non-fasted animals by collagenase digestion and Ficoll-
histopaque density gradient separation as described (13). Glu-
cose-stimulated insulin secretion wasmeasured using a BioRep
perifusion system for which 25 similarly shaped and sized islets
were hand-selected using a microscope. Islets were incubated
in 3mM glucose for 25min followed by stimulation with 20mM
glucose for 40 min and finally 20 mM KCl for 5 min prior to
returning to 3 mM glucose. Medium was collected every 1–3
min to assess insulin secretion. Secreted insulin in response to
glucose was normalized to KCl-mediated insulin secretion.
Statistical Analysis—A two-tailed Student’s t test was used to
compare two groups in Microsoft Excel. Where indicated,
experiments comparing multiple groups were analyzed by
ANOVA inGraph Pad Prism 6.0. p 0.05 was considered to be
statistically significant. Variance was estimated using the stan-
dard error of the mean.
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